ScreenPoint Medical’s Board of Directors has announced the appointment of Peter Kroese as the new Chief Executive Officer (CEO) of the breast artificial intelligence (AI) company. Kroese served as the company COO for over five years. Image courtesy: ScreenPoint Medical
May 6, 2024 — ScreenPoint Medical’s Board of Directors has announced the appointment of Peter Kroese as the new Chief Executive Officer (CEO) of the breast artificial intelligence (AI) company. The creator of Transpara reported the significant transition in its leadership as Mark Koeniguer, the current CEO, stepped down from his position, noting Koeniguer served as CEO since 2022 and was instrumental in ScreenPoint's commercial growth and success over the past 2 years.
According to the company’s written statement, Kroese takes the role after serving as COO of ScreenPoint for over five years. During that time, he has managed the transition of the company from an early start-up to a thriving enterprise with hundreds of customers using ScreenPoint's flagship Transpara software to support millions of scans a year.
Sir Michael Brady, Chairman of the Board at ScreenPoint Medical and a co-founder of the company, expressed enthusiasm about Pieter's appointment, stating: "Pieter's remarkable leadership qualities, coupled with his depth of knowledge of our product and industry, make him the perfect choice to lead ScreenPoint into the future. His strategic mindset and commitment to excellence align perfectly with our company mission of early breast cancer detection. Pieter has been an integral part of our growth to date and will provide seamless leadership through this transition into our next chapter for our customers, partners, and team."
"I am thrilled to lead ScreenPoint into its next phase of growth and innovation," said Kroese, adding, "I am deeply committed to building upon the strong foundation we have and continuing to work closely with our talented team to drive continued success. We are already expanding screening capacity and capability through proven reader support – we look forward to increasing our ability to support providers and women moving forward."
Author of "No Longer Radical" and over a hundred peer-reviewed publications on breast imaging, Rachel Brem, MD, George Washington University Hospital, is a Transpara user and ScreenPoint Board Member. Dr. Brem welcomed Kroese with the following: "Pieter has been an integral part of the ScreenPoint team for years. I am confident that his leadership will continue to deliver product excellence: earlier detection with outstanding reading workflow and improved patient outcomes. We continue to see these results from clinical sites all over the world, including many here in the United States. No other Breast AI solution has demonstrated the same results as Transpara, and I am confident that the team will continue to push on these frontiers under Pieter's leadership."
In its written statement about the transition, the company noted that its entire team at ScreenPoint extends gratitude to Mark Koeniguer and wishes him every success in the future, while warmly welcoming Kroese into his new role as CEO.
The company translates cutting edge machine learning research into technology accessible by radiologists to improve screening workflow, decision confidence and breast cancer risk assessment. It notes that Screenpoint is trusted by radiologists globally due to being developed by machine learning (ML) and image analysis experts, and is updated with user feedback from world-renowned breast imagers.
More information: www.screenpoint-medical.com
September 16, 2026 
